University Health Network
Co-applicant: Dr. Mark Minden
Targeting repressive chromatin complex mutations in acute myeloid leukemia
PRC2 is a multi-protein complex that controls the genes important for normal blood cell development and leukemia progression. Mutations in the genes encoding the components of PRC2 are found in myelodysplasia, myeloproliferative disorders and Acute Myeloid Leukemia (AML) and are often associated with poor prognosis. We have previously investigated AML patient samples and have shown that drugs targeting the PRC2 complex drastically reduced the ability of these cells to grow thus providing a potential option of treatment. We propose to undertake further studies to understand the role of the mutant PRC2 complex in AML. This information gathered here will provide justification to explore PRC2 as a drug target, or biomarker for other drugs, and help identify an important patient population that may most benefit from such agents.